Finance

Protein therapeutics developer announces proposed common stock offering

Published in Gene Therapy Weekly, September 1st, 2005

ZymoGenetics, Inc. (ZGEN) announced that it intends to offer 6,500,000 primary shares of common stock in a public offering pursuant to an effective shelf registration statement.

ZymoGenetics has granted the underwriters in the offering an option to purchase 975,000 shares of common stock to cover over-allotments. Merrill Lynch & Co. will act as the lead manager for the offering. Pacific Growth Equities, LLC, Bear, Stearns & Co. Inc. and Piper Jaffray & Co. will act as co-managers.

ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-09-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry